prikaz prve stranice dokumenta Plasminogen activator inhibitor-1 (PAI-1) in patients with primary hypertension
  Download
PDF 739.51 KB
master's thesis
Plasminogen activator inhibitor-1 (PAI-1) in patients with primary hypertension
2024. urn:nbn:hr:171:594286
Venstad, Casper Reynols
University of Split
School of Medicine

Cite this document

Venstad, C. R. (2024). Plasminogen activator inhibitor-1 (PAI-1) in patients with primary hypertension (Master's thesis). Split: University of Split, School of Medicine. Retrieved from https://urn.nsk.hr/urn:nbn:hr:171:594286

Venstad, Casper Reynols. "Plasminogen activator inhibitor-1 (PAI-1) in patients with primary hypertension." Master's thesis, University of Split, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:171:594286

Venstad, Casper Reynols. "Plasminogen activator inhibitor-1 (PAI-1) in patients with primary hypertension." Master's thesis, University of Split, School of Medicine, 2024. https://urn.nsk.hr/urn:nbn:hr:171:594286

Venstad, C. R. (2024). 'Plasminogen activator inhibitor-1 (PAI-1) in patients with primary hypertension', Master's thesis, University of Split, School of Medicine, accessed 19 March 2025, https://urn.nsk.hr/urn:nbn:hr:171:594286

Venstad CR. Plasminogen activator inhibitor-1 (PAI-1) in patients with primary hypertension [Master's thesis]. Split: University of Split, School of Medicine; 2024 [cited 2025 March 19] Available at: https://urn.nsk.hr/urn:nbn:hr:171:594286

C. R. Venstad, "Plasminogen activator inhibitor-1 (PAI-1) in patients with primary hypertension", Master's thesis, University of Split, School of Medicine, Split, 2024. Available at: https://urn.nsk.hr/urn:nbn:hr:171:594286

Please login to the repository to save this object to your list.
Metadata
TitlePlasminogen activator inhibitor-1 (PAI-1) in patients with primary hypertension
Title (croatian)Inhibitor aktivatora plazminogena-1 (PAI-1) u pacijenata s primarnom hipertenzijom
AuthorCasper Reynols Venstad
MentorJoško Božić (mentor)
Committee memberMarino Vilović (predsjednik povjerenstva)
Committee memberDuška Glavaš (član povjerenstva)
Committee memberTina Tičinović Kurir (član povjerenstva)
GranterUniversity of Split
School of Medicine
Split
Defense date and country2024-07-04, Croatia
Scientific / art field,
discipline and subdiscipline		BIOMEDICINE AND HEALTHCARE
Clinical Medical Sciences
Pathophysiology
Abstract
Objectives: The primary objective of this study was to evaluate the differences in plasminogen activator inhibitor-1 (PAI-1) serum concentrations between hypertensive patients and healthy controls and to assess the potential impact of obesity on PAI-levels within the hypertensive population. Subjects and methods: This cross-sectional study enrolled two groups, each consisting of 40 participants. One group consisted of patients diagnosed with hypertension, while the other one consisted of... More age- and sex-matched healthy controls. Serum PAI-1 concentrations were measured in a cohort of patients with arterial hypertension and age- and sex-matched healthy controls. Participants were categorized into obese and non-obese groups based on body mass index, with 30 kg/m2 set as the threshold. Clinical parameters including blood pressure, lipid profile, and anthropometric data were collected. Correlation analysis between PAI-1 levels and various clinical and laboratory parameters was performed using Pearson's correlation coefficient. Results: PAI-1 serum concentrations were significantly higher in patients with arterial hypertension in comparison to healthy age- and sex-matched controls (4327.52 ± 1100.26 pg/mL vs. 2278.35 ± 1046.43 pg/mL, P < 0.001). Furthermore, PAI-1 serum concentrations were significantly higher in obese hypertensive patients when compared to non-obese hypertensive patients (4445.32 ± 1146.36 pg/mL vs. 4173.88 ± 1211.33 pg/mL, P = 0.031). A significant positive correlation was found between PAI-1 levels and diastolic blood pressure (r = 0.314, P = 0.004). No significant correlations were found between PAI-1 and age, BMI, total cholesterol, LDL-C, HDL-C, or triglycerides, indicating that these factors may not directly influence PAI-1 levels in hypertensive patients. Conclusion: Overall, these findings suggest that PAI-1 may be a useful biomarker for cardiovascular risk stratification in hypertensive patients. In addition, observations concerning difference in PAI-1 depending on body mass index highlight the impact of obesity on hypertensive pathology. Less
Abstract (croatian)
Ciljevi: Primarni cilj ove studije bio je procijeniti razlike u koncentracijama PAI-1 u serumu između hipertenzivnih bolesnika i zdravih ispitanika te procijeniti potencijalni utjecaj pretilosti na razine PAI-1 unutar hipertenzivne populacije. Ispitanici i metode: Studija je uključivala dvije skupine, svaka od 40 sudionika. Jedna skupina sastojala se od bolesnika s dijagnozom hipertenzije, dok je druga skupina uključivala dobno i spolno usklađene zdrave ispitanike. Koncentracije PAI-1 u... More serumu mjerene su u kohorti bolesnika s arterijskom hipertenzijom i dobno i spolno usklađenim zdravim ispitanicima. Sudionici su kategorizirani u pretile i nepretile skupine prema indeksu tjelesne mase, s pragom postavljenim na 30 kg/m². Prikupljeni su klinički parametri, uključujući krvni tlak, lipidni profil i antropometrijske podatke. Korelacijska analiza između razina PAI-1 i različitih kliničkih i laboratorijskih parametara provedena je korištenjem Pearsonovog korelacijskog koeficijenta. Rezultati: Koncentracije PAI-1 u serumu bile su značajno više u bolesnika s arterijskom hipertenzijom u usporedbi sa zdravim dobno i spolno usklađenim ispitanicima (4327,52 ± 1100,26 pg/mL naspram 2278,35 ± 1046,43 pg/mL, P < 0,001). Nadalje, koncentracije PAI-1 u serumu bile su značajno više u pretilih hipertenzivnih bolesnika u usporedbi s nepretilim hipertenzivnim bolesnicima (4445,32 ± 1146,36 pg/mL naspram 4173,88 ± 1211,33 pg/mL, P = 0,031). Pronađena je značajna pozitivna korelacija između razina PAI-1 i dijastoličkog krvnog tlaka (r = 0,314, P = 0,004). Nisu pronađene značajne korelacije između PAI-1 i dobi, BMI-a, ukupnog kolesterola, LDL-C-a, HDL-C-a ili triglicerida, što ukazuje na to da ovi faktori možda ne utječu izravno na razine PAI-1 u hipertenzivnih bolesnika. Zaključak: Ovi rezultati sugeriraju da PAI-1 može biti koristan biomarker za stratifikaciju kardiovaskularnog rizika u hipertenzivnih bolesnika. Osim toga, zapažanja o razlikama u razinama PAI-1 ovisno o indeksu tjelesne mase naglašavaju utjecaj pretilosti na patologiju hipertenzije. Less
Keywords
Keywords (croatian)
Languageenglish
URN:NBNurn:nbn:hr:171:594286
Study programmeTitle: Medical Studies in English
Study programme type: university
Study level: integrated undergraduate and graduate
Academic / professional title: doktor/doktorica medicine (doktor/doktorica medicine)
Type of resourceText
File originBorn digital
Access conditionsOpen access
Embargo expiration date: 2024-07-04
Terms of useLicence In copyright icon
Created on2024-07-04 12:44:14
accessibility

closeAccessibilityrefresh

If you wish to permanently save changes, click on Save, if not - your settings will be reset when you restart the browser.